We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

75 hedge funds and large institutions have $180M invested in Viracta Therapeutics, Inc. Common Stock in 2013 Q2 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

92% less call options, than puts

Call options by funds: $209K | Put options by funds: $2.58M

Holders
75
Holders Change
+75
Holders Change %
–
% of All Funds
2.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
75
Increased
–
Reduced
–
Closed
–
Calls
$209K
Puts
$2.58M
Net Calls
-$2.37M
Net Calls Change
-$2.37M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

VIRX Hedge Fund Activity: Q2 2013 in Review

75 of the 3,075 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2013, worth a combined $180M.

Buyers outnumbered sellers: 75 funds opened new VIRX positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.

  • 75 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $180M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2013.
  • 75 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2013 and 0 closed out, a net change of +75 holders.

Based on aggregated 13F filings for Q2 2013.